Literature DB >> 12873613

Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake.

Donard S Dwyer1, Dallas Donohoe.   

Abstract

Many antipsychotic drugs disturb the regulation of glucose metabolism in patients treated for schizophrenia. The goal of the present studies was to determine if these antipsychotic drugs produce hyperglycemia in mice in relation to their ability to interfere with glucose uptake and utilization. Male C57BL/6 mice were injected with a panel of typical and atypical antipsychotic drugs and blood glucose levels were determined periodically over a 3- to 6-h time interval. The atypical drugs, clozapine, desmethylclozapine, quetiapine, and loxapine, and the original antipsychotic, chlorpromazine, induced significant hyperglycemia in the mice in accordance with their effects on glucose transport. By contrast, haloperidol and sulpiride, which have little effect on glucose uptake, did not induce hyperglycemia. Risperidone produced a modest elevation of blood glucose levels, but only at a low dose of the drug. Cytochalasin B, a specific inhibitor of the glucose transporter (GLUT) protein, produced significant hyperglycemia in the mice. Overall, there was a strong correlation between the ability of a drug to inhibit glucose transport in vitro and its ability to induce hyperglycemia in vivo. Finally, the drugs that produced hyperglycemia in mice have been linked to the development of diabetes in patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12873613     DOI: 10.1016/s0091-3057(03)00079-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  26 in total

Review 1.  Acute hyperglycemia associated with short-term use of atypical antipsychotic medications.

Authors:  T Vivian Liao; Stephanie V Phan
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

Review 2.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

3.  Metabolic issues in schizophrenic patients receiving antipsychotic treatment.

Authors:  Aditi Gupta; Gora Dadheech; Dharamveer Yadav; Praveen Sharma; Shiv Gautam
Journal:  Indian J Clin Biochem       Date:  2014-01-23

Review 4.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

Review 5.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

Authors:  A A Verhaegen; L F Van Gaal
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

Review 6.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  A novel insulin sensitizer drug candidate-BGP-15-can prevent metabolic side effects of atypical antipsychotics.

Authors:  Zsuzsanna Literati-Nagy; Kálmán Tory; Botond Literáti-Nagy; Attila Kolonics; László Vígh; László Vígh; József Mandl; Zoltán Szilvássy
Journal:  Pathol Oncol Res       Date:  2012-06-30       Impact factor: 3.201

8.  Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice.

Authors:  Candice M Klingerman; Michelle E Stipanovic; Mohammad Bader; Christopher J Lynch
Journal:  Schizophr Bull       Date:  2013-01-17       Impact factor: 9.306

Review 9.  Pancreatic Islet Responses to Metabolic Trauma.

Authors:  Susan J Burke; Michael D Karlstad; J Jason Collier
Journal:  Shock       Date:  2016-09       Impact factor: 3.454

10.  Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation.

Authors:  Yvette E Savoy; Michael A Ashton; Matthew W Miller; Frank M Nedza; Douglas K Spracklin; Mark H Hawthorn; Hans Rollema; F Fatima Matos; Eva Hajos-Korcsok
Journal:  Schizophr Bull       Date:  2008-08-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.